Veradigm | MDRX - Cost Of Sales


Veradigm reported $124.74M in Cost of Sales for its fiscal quarter ending in December of 2022.





Cost Of Sales Change Date
Alcidion AUD 6.82M 1.16M Dec/2025
Ambu A/S DKK 625M 14M Mar/2026
Amplifon EUR 527.19M 77.51M Jun/2026
Cardinal Health USD 58.54B 4.82B Mar/2026
Centene USD 48.98B 4.59B Jun/2026
Charles River Laboratories USD 716.51M 5.76M Mar/2026
Cigna USD 65.13B 2.72B Jun/2026
Coloplast 2.31B 110M Dec/2025
Convatec Group USD 515.3M 270.15M Dec/2024
CVS Health USD 84.8B 7.32B Mar/2026
Diasorin EUR 101M 7.58M Mar/2026
Elevance Health USD 38.07B 75M Dec/2025
General Electric Aerospace USD 8.89B 736M Jun/2026
Gulf Medical Proj AED 151.05M 11.52M Dec/2025
Humana USD 26.54B 1.15B Mar/2025
IQVIA Holdings USD 3.22B 141M Jun/2026
Laboratory Of America USD 2.7B 97.8M Jun/2026
Maximus USD 984M 62.68M Mar/2026
McKesson USD 92.25B 10.22B Mar/2026
Med Life RON 171.54M 112.24M Mar/2026
Molina Healthcare USD 9.48B 294M Jun/2026
Omnicell USD 159.27M 10.24M Jun/2026
Oriola-kd EUR 11.4M 450.2M Mar/2026
Owens Minor USD 436.92M 32.62M Dec/2025
Quest Diagnostics USD 2.05B 64M Jun/2026
Rede D'or Sao Luiz BRL 11.12B 4.84B Mar/2026
Siemens Healthineers EUR 3.31B 226M Jun/2026
Sonova Holding CHF 539.4M 11.5M Dec/2025
UnitedHealth USD 86.31B 8.41B Mar/2026
Veeva Systems USD 220.92M 7.45M Mar/2026
Veradigm USD 124.74M 56.25M Dec/2022
Xerox USD 1.14B 104M Jun/2025